Microporous collagen matrices for bioprinting human tissues

Daniel Reynolds and Jennifer Lewis

3D bioprinting has tremendous potential in tissue engineering and drug development. However, most biological inks and matrices developed for bioprinting exhibit a narrow “printing window”. The ability to generate biomaterials that exhibit excellent printability, while retaining key properties that promote cell spreading, proliferation, and migration would open new avenues for 3D bioprinting of human tissue models for drug discovery, disease modeling, and therapeutic repair and regeneration.

Our team has recently developed and filed IP on a new class of micro-porous biomaterials for 3D bioprinting that are both highly printable and permissive to key cellular processes. Our work was originally supported by the NCI Cancer Tissue Engineering Collaborative; hence, to date, we have focused on demonstrating its utility in an immuno-oncology model. However, our new microPOROS bioprinting platform can be harnessed to replicate a wide range of complex tissue microenvironments, including models for preclinical drug development, in-clinic precision medicine, and vascularized metabolic tissues for therapeutic applications.

BTIP Agenda

• In-person convening and light dinner: 5:30 – 5:45pm Eastern Time (US and Canada)
• Zoom presentation: 5:45 – 6:45pm Eastern Time (US and Canada)
• In-person networking: 6:45 – 7:00pm Eastern Time (US and Canada)

Contact

For more information about BTIP or to request an invitation, please contact Ifat Rubin-Bejerano, Senior Director of Translational Research.